Author's posts
The Biotech Paradox Of 2020: A Year In Review
2020 was an incredibly paradoxical year for those of us in biotech: the striking dichotomy of simultaneously experiencing agonizing tragedy alongside buoyant optimism.
Biotech: The Featherweight Champion Of The Markets
Biopharma is a relatively small sector of the markets, but a much larger share of new equity issuances – and it’s been growing in size. It’s now the largest subsector in the Russell 2000
It’s Raining Biotech SPACs!
SPACs are all the rage today, and in recent quarters have hit the biotech sector in a big way.
Evolution Of The Biotech IPO Markets From Busted To Booming
Biotech IPOs are booming today, but that certainly wasn’t always the case. The author explores two decades of structural changes to the IPO market and process.
The Record-Breaking Biotech Funding Tsunami Of 1H2020
Biotech equity funding across venture capital and the public markets reached record-breaking levels in 2Q 2020
Value Creation And Destruction: Dispersion Of Performance In Biotech IPOs
The current biotech IPO market remains surprisingly strong and resilient. One of the characteristics of biotech IPO performance over the past eight years has been its dispersion, a feature that continues in the current environment. The author examines …
Booming VC-Backed Biopharma: Strong Market Despite Pandemic
Biopharma Venture Capital funding hit all-time-highs during the first quarter of 2020. Author shares the data and reflects on the market in light of COVID.
Strategic Planning In Biotech During A Pandemic Crisis
Leading an R&D-stage biotech during the COVID pandemic crisis demands deep strategic planning and adaptability around future scenarios.
BioPharma M&A Drives More Efficient Resource Allocation
By improving the efficiency of allocating the scarce resources of talent, science, and capital across the sector, biopharma M&A drives huge benefits – and much of biotech’s current success in advancing innovation stems from these long term positive imp…
Wither New Biotech Startups?
Biotech venture capital funding remains robust, but a troubling trendline in venture formation suggests a change in new startup activity
